Tyme Technologies Inc (NASDAQ:TYME) major shareholder Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $1.11, for a total transaction of $55,500.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Michael Demurjian also recently made the following trade(s):
- On Monday, July 22nd, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The stock was sold at an average price of $1.18, for a total transaction of $59,000.00.
Shares of TYME opened at $1.11 on Friday. The stock’s 50 day simple moving average is $1.18. Tyme Technologies Inc has a 1-year low of $0.92 and a 1-year high of $4.64. The stock has a market cap of $125.39 million, a PE ratio of -3.47 and a beta of 0.41.
Separately, Zacks Investment Research cut shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th.
Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc boosted its position in Tyme Technologies by 157.0% during the fourth quarter. Legal & General Group Plc now owns 16,127 shares of the company’s stock worth $60,000 after acquiring an additional 9,853 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Tyme Technologies during the 4th quarter valued at $47,000. SG Americas Securities LLC acquired a new position in shares of Tyme Technologies during the 1st quarter valued at $27,000. Deutsche Bank AG lifted its holdings in shares of Tyme Technologies by 12.8% during the 4th quarter. Deutsche Bank AG now owns 136,105 shares of the company’s stock valued at $501,000 after acquiring an additional 15,483 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in shares of Tyme Technologies during the 4th quarter valued at $58,000. 19.83% of the stock is owned by institutional investors and hedge funds.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Featured Story: Fundamental Analysis
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.